The latest price of sotoraxibu is disclosed: the generic drug only costs RMB 2,000 to 3,000, which is far lower than the price of the original drug.

Sotorasib is a new anti-cancer drug that belongs to the KRAS G12C inhibitor class. KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key oncogene that plays a role in many cancers. Sotoracib is mainly used to treat non-small cell lung cancer (NSCLC), a common type of lung cancer.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

The drug is unique in that it targets the G12C mutation of the KRAS gene. This mutated form is prevalent in many types of cancer and causes abnormal growth and spread of cancer cells. Sotorasiib blocks abnormal signal transduction by specifically inhibiting the KRAS G12C mutation, thereby inhibiting the growth and division of cancer cells.

Clinical trials have shown that sotoraxib has achieved significant efficacy in some NSCLC patients who have received other treatments with limited efficacy. This makes sotoracib an innovative treatment option, especially for patients who carry the KRAS G12C mutation.

However, drug treatment always involves individual differences and potential side effects. Before using sotorasiib or any other medication, patients should receive a detailed medical evaluation and treatment under the supervision of a professional physician. Doctors will consider the patient's specific situation, develop the most appropriate treatment plan, and monitor the patient's efficacy and safety. Overall, sotoraxib represents an important advance in cancer treatment, providing a new treatment option for some patients.